Among men who had persistent prostate-specific antigen (PSA) after radical prostatectomy (RP), a higher preoperative PSA ...

Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...

The phase 2/3 NRG GU002 trial (NCT03070886) evaluated whether adding 6 cycles of docetaxel after radiation and androgen ...

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk. Patients with a ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

Five-year phase 3 results support hypofractionated radiotherapy as a shorter treatment option after prostatectomy but raise concern about late GU toxicity.

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Prostate cancer has a well-earned reputation for being one of the more trackable malignancies in medicine. Since the mid-1980s, a single blood test measuring prostate-specific antigen, or PSA, has ...

Prostate cancer is common. About 200 in every 1,000 Australian men will be told they have prostate cancer by the age of 85. But the chance of dying from it is much lower: around 18 in 1,000 cases.

Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...